November 23, 2022 Regulatory AcuCort signs its first commercial agreement for the company’s drug Zeqmelit™
November 11, 2022 Regulatory AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
October 19, 2022 Regulatory AcuCort receives a granted patent in Canada for the company’s drug Zeqmelit™
September 28, 2022 Non Regulatory AcuCort reports positive results from the company’s questionnaire study about allergy treatments
September 27, 2022 Regulatory AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency
September 22, 2022 Non Regulatory AcuCort presents at Nordic Life Science Days in Malmö on September 29, 2022
August 16, 2022 Regulatory AcuCort receives marketing authorization for the drug Zeqmelit by the Danish Medicines Agency
August 12, 2022 Regulatory AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)
June 8, 2022 Regulatory AcuCort’s application for ethical review for a questionnaire study on allergy treatment is approved
April 28, 2022 Regulatory AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)
April 26, 2022 Regulatory AcuCort applies for ethical review for a questionnaire study on allergy treatment
March 1, 2022 Regulatory AcuCort is exempted from the application fee by the U.S. Food and Drug Administration
February 22, 2022 Regulatory AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT®
February 17, 2022 Regulatory AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®